Pharmacophore an International Research Journal
Pharmacophore
Submit Manuscript
Open Access | Published: 2023 - Issue 2

Analysis of the Antimicrobial Drugs Market in Russia Download PDF


, , , , ,
Abstract

Most inflammatory diseases in the human body are provoked by microorganisms. Bronchitis, pneumonia, otitis media, conjunctivitis, cystitis, endometritis, inflammation of the fallopian tubes and ovaries, and many other diseases in modern treatment protocols of all countries contain antimicrobial substances. Treatment of various bacterial infections (for example, chlamydia, scarlet fever, streptodermia, meningitis, and tuberculosis) is impossible without antimicrobial therapy. Viral diseases (herpes infections, chickenpox, hepatitis B and C, HIV) at the present stage are susceptible to the effects of antiviral drugs. Fungal diseases of the skin, nails, mucous membranes, and systemic mycoses are treated with antibiotics. Protozoa cause such protozoal infections as giardiasis, amoebic dysentery, trichomoniasis, malaria, and toxoplasmosis. In such infections, antiprotozoal antimicrobial medications are prescribed. Thus, the spectrum of effects of these agents is directed at bacteria, fungi, viruses, and protozoa. This article provides a brief description of the types of antimicrobials, as well as an analysis of the antimicrobial drugs market in Russia.

Cite this article
Vancouver
Khazamova SO, Lazareva NV, Semenova LV, Lukyanov GI, Kolosova OY, Kamalova ON. Analysis of the Antimicrobial Drugs Market in Russia. Pharmacophore. 2023;14(2):30-6. https://doi.org/10.51847/l21Qr0rK1S
APA
Khazamova, S. O., Lazareva, N. V., Semenova, L. V., Lukyanov, G. I., Kolosova, O. Y., & Kamalova, O. N. (2023). Analysis of the Antimicrobial Drugs Market in Russia. Pharmacophore, 14(2), 30-36. https://doi.org/10.51847/l21Qr0rK1S

QR code:

Short Link:
Views: 220

Downloads: 51
Quick Access

Pharmacophore
ISSN: 2229-5402

Pharmacophore
© 2024 All rights reserved
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.